Expertise in
8
conditions

Dr. Regan Rostorfer

Hematology
Orlando Health Central Oncology Pharmacy
9900 W Colonial Dr, 
Ocoee, FL 
Offers Telehealth
Expertise in
8
conditions
Orlando Health Central Oncology Pharmacy
9900 W Colonial Dr, 
Ocoee, FL 

Overview

Regan Rostorfer is a Hematologist in Ocoee, Florida. Dr. Rostorfer is highly rated in 8 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in FL

Hospital Affiliations

Orlando Health
Orlando Health South Lake Hospital
Orlando Health-Health Central Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 27 Less Insurance Carriers -

Locations

Orlando Health Central Oncology Pharmacy
9900 W Colonial Dr, Ocoee, FL 34761
Other Locations
Orlando Health Scripts
1400 S Orange Ave, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug, Biological
Study Drugs: Trilaciclib, Cylophosphamide, Doxorubicin, Paclitaxel, Carboplatin, Pembrolizumab
Study Phase: Phase 2
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201)
Enrollment Status: Completed
Publish Date: April 03, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 4 Less Clinical Trials

2 Total Publications

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2019
Similar Doctors
Expertise in
14
conditions
Dr. Don Eslin
Hematology | Oncology
Expertise in
14
conditions
Dr. Don Eslin
Hematology | Oncology

Orlando Health Arnold Palmer Hospital For Children

92 W Miller St, 
Orlando, FL 
 (0.2 miles away)
407-841-5111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Don Eslin is a Hematologist and an Oncologist in Orlando, Florida. Dr. Eslin is highly rated in 14 conditions, according to our data. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Medulloblastoma, Glioma, and Bone Marrow Aspiration.

Expertise in
11
conditions
Dr. Samer Khaled
Hematology
Expertise in
11
conditions
Dr. Samer Khaled
Hematology

Orlando Health Scripts

1400 S Orange Ave, 
Orlando, FL 
 (0.1 miles away)
321-841-8650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samer Khaled is a Hematologist in Orlando, Florida. Dr. Khaled is highly rated in 11 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
29
conditions
Dr. Sonalee K. Shroff
Hematology | Oncology
Expertise in
29
conditions
Dr. Sonalee K. Shroff
Hematology | Oncology

Florida Cancer Specialists Pl

2501 N Orange Ave Ste 389, 
Orlando, FL 
 (3.8 miles away)
407-898-5452
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonalee Shroff is a Hematologist and an Oncologist in Orlando, Florida. Dr. Shroff is highly rated in 29 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Shroff is currently accepting new patients.

Frequently Asked Questions about Dr. Regan Rostorfer

How do I make an appointment with Dr. Regan Rostorfer?

You can book an appointment with Dr. Regan Rostorfer by calling their office at 321-841-5169. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Regan Rostorfer a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Regan Rostorfer is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Regan Rostorfer specialize in?

While Dr. Regan Rostorfer is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Regan Rostorfer participate in research or clinical trials?

Yes. Dr. Regan Rostorfer has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Regan Rostorfer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Regan Rostorfer accept my insurance?

Dr. Regan Rostorfer accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 321-841-5169 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rostorfer's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile